186 related articles for article (PubMed ID: 37892820)
1. Celecoxib Suppresses NF-κB p65 (RelA) and TNFα Expression Signaling in Glioblastoma.
Ahsan H; Malik SI; Shah FA; El-Serehy HA; Ullah A; Shah ZA
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892820
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines.
Li ZY; Li QZ; Chen L; Chen BD; Wang B; Zhang XJ; Li WP
Neurochem Res; 2016 Dec; 41(12):3192-3205. PubMed ID: 27632183
[TBL] [Abstract][Full Text] [Related]
3. NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways.
Avci NG; Ebrahimzadeh-Pustchi S; Akay YM; Esquenazi Y; Tandon N; Zhu JJ; Akay M
Sci Rep; 2020 Aug; 10(1):13352. PubMed ID: 32770097
[TBL] [Abstract][Full Text] [Related]
4. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway.
Sareddy GR; Geeviman K; Ramulu C; Babu PP
J Neurooncol; 2012 Jan; 106(1):99-109. PubMed ID: 21847707
[TBL] [Abstract][Full Text] [Related]
5. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
6. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway.
Tang Q; Cao H; Tong N; Liu Y; Wang W; Zou Y; Xu L; Zeng Z; Xu W; Yin Z; Ma W; Wang Q
Phytomedicine; 2022 May; 99():154016. PubMed ID: 35278900
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of p65 attenuates celecoxib-induced cell death in MDA-MB-231 human breast cancer cell line.
Wang L; Kang F; Li J; Zhang J; Shan B
Cancer Cell Int; 2013 Feb; 13(1):14. PubMed ID: 23402310
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor PDCD4 inhibits NF-κB-dependent transcription in human glioblastoma cells by direct interaction with p65.
Hwang SK; Baker AR; Young MR; Colburn NH
Carcinogenesis; 2014 Jul; 35(7):1469-80. PubMed ID: 24413684
[TBL] [Abstract][Full Text] [Related]
9. Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells.
Tchoghandjian A; Jennewein C; Eckhardt I; Rajalingam K; Fulda S
Cell Death Dis; 2013 Mar; 4(3):e564. PubMed ID: 23538445
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol converts NF-κB into a tumor suppressor in glioblastoma with defined antioxidative properties.
Volmar MNM; Cheng J; Alenezi H; Richter S; Haug A; Hassan Z; Goldberg M; Li Y; Hou M; Herold-Mende C; Maire CL; Lamszus K; Flüh C; Held-Feindt J; Gargiulo G; Topping GJ; Schilling F; Saur D; Schneider G; Synowitz M; Schick JA; Kälin RE; Glass R
Neuro Oncol; 2021 Nov; 23(11):1898-1910. PubMed ID: 33864076
[TBL] [Abstract][Full Text] [Related]
11. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.
Haemmig S; Baumgartner U; Glück A; Zbinden S; Tschan MP; Kappeler A; Mariani L; Vajtai I; Vassella E
Cell Death Dis; 2014 Jun; 5(6):e1279. PubMed ID: 24901050
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
13. The positive regulatory loop of TCF4N/p65 promotes glioblastoma tumourigenesis and chemosensitivity.
Hu Y; Zhang B; Lu P; Wang J; Chen C; Yin Y; Wan Q; Wang J; Jiao J; Fang X; Pu Z; Gong L; Ji L; Zhu L; Zhang R; Zhang J; Yang X; Wang Q; Huang Z; Zou J
Clin Transl Med; 2022 Sep; 12(9):e1042. PubMed ID: 36116131
[TBL] [Abstract][Full Text] [Related]
14. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
[TBL] [Abstract][Full Text] [Related]
15. NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug.
Caporali S; Levati L; Graziani G; Muzi A; Atzori MG; Bonmassar E; Palmieri G; Ascierto PA; D'Atri S
J Transl Med; 2012 Dec; 10():252. PubMed ID: 23259744
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II.
Wang D; Westerheide SD; Hanson JL; Baldwin AS
J Biol Chem; 2000 Oct; 275(42):32592-7. PubMed ID: 10938077
[TBL] [Abstract][Full Text] [Related]
17. Caspase-3-mediated cleavage of p65/RelA results in a carboxy-terminal fragment that inhibits IkappaBalpha and enhances HIV-1 replication in human T lymphocytes.
Coiras M; López-Huertas MR; Mateos E; Alcamí J
Retrovirology; 2008 Dec; 5():109. PubMed ID: 19046417
[TBL] [Abstract][Full Text] [Related]
18. Small GTPase RHOE/RND3, a new critical regulator of NF-κB signalling in glioblastoma multiforme?
Sun Q; Dong H; Li Y; Yuan F; Xu Y; Mao S; Xiong X; Chen Q; Liu B
Cell Prolif; 2019 Sep; 52(5):e12665. PubMed ID: 31332862
[TBL] [Abstract][Full Text] [Related]
19. Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529.
Wang D; Baldwin AS
J Biol Chem; 1998 Nov; 273(45):29411-6. PubMed ID: 9792644
[TBL] [Abstract][Full Text] [Related]
20. Cyclic-AMP Increases Nuclear Actin Monomer Which Promotes Proteasomal Degradation of RelA/p65 Leading to Anti-Inflammatory Effects.
Hawkins JW; McNeill MC; Ebrahimighaei R; Mellor HH; Newby AC; Bond M
Cells; 2022 Apr; 11(9):. PubMed ID: 35563720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
